Effect of ketamine and magnesium sulfate in refractory chronic cluster headache

The effect of combination therapy with ketamine and magnesium sulfate on refractory chronic cluster headache

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240305061175N1

Enrollment

Registered

2024-04-04

Start date

2024-04-13

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory chronic cluster headache. Chronic cluster headache, intractable

Interventions

Intervention group:After filling out the personal consent form, the patients with chronic cluster headache resistant to treatment are admitted to the hospital, and before receiving the treatment proto

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ??????? ????? ?????? ???? ?? ?????? ????? ?????? ?? ?? ????? ?????? ????????? ??? ????? ???? ???? ? ?????? ????? heart failure?? coronary artery disease ??????? ?? ??????? ?????? ?? ???? ????? ????

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Change in the frequency of headache attacks. Timepoint: Patients would be evaluated in two weeks, one month and two months after receiving the treatment protocol. Method of measurement: Researcher made questionnaire about the frequency of the attacks which is answered by the patient during the survey.;Change in the headache attack severity. Timepoint: Patients would be evaluated in two weeks, one month and two months after receiving the treatment protocol. Method of measurement: The universal pain assessment tool(UPAT).;Change in the quality of life of patients. Timepoint: Patients would be evaluated in two weeks, one month and two months after receiving the treatment protocol. Method of measurement: The World Health Organization Quality of Life Brief Version(WHOQOL-BREF).;Change in the duration of each headache attack. Timepoint: Patients would be evaluated in two weeks, one month and two months after receiving the treatment protocol. Method of measurement: Researcher made questionnaire about the frequency of the attacks which is answered by the patient during the survey.;Change in the frequency of hospitalization due to cluster headache attack. Timepoint: Patients would be evaluated in two weeks, one month and two months after receiving the treatment protocol. Method of measurement: Researcher made questionnaire about the frequency of hospitalization due to cluster headache attack which is answered by the patient during the survey.	—

Measure

Time frame

Change in the frequency of headache attacks. Timepoint: Patients would be evaluated in two weeks, one month and two months after receiving the treatment protocol. Method of measurement: Researcher made questionnaire about the frequency of the attacks which is answered by the patient during the survey.;Change in the headache attack severity. Timepoint: Patients would be evaluated in two weeks, one month and two months after receiving the treatment protocol. Method of measurement: The universal pain assessment tool(UPAT).;Change in the quality of life of patients. Timepoint: Patients would be evaluated in two weeks, one month and two months after receiving the treatment protocol. Method of measurement: The World Health Organization Quality of Life Brief Version(WHOQOL-BREF).;Change in the duration of each headache attack. Timepoint: Patients would be evaluated in two weeks, one month and two months after receiving the treatment protocol. Method of measurement: Researcher made questionnaire about the frequency of the attacks which is answered by the patient during the survey.;Change in the frequency of hospitalization due to cluster headache attack. Timepoint: Patients would be evaluated in two weeks, one month and two months after receiving the treatment protocol. Method of measurement: Researcher made questionnaire about the frequency of hospitalization due to cluster headache attack which is answered by the patient during the survey.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarhad Assarzadegan

Shahid Beheshti University of Medical Sciences

info@sbmu.ac.ir+98 21 7343 3000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026